Beijing Biostar Pharms (2563) Fundamentals 2026 — Revenue Analysis | SniperIQ
Beijing Biostar Pharms (2563) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of HK$769M, trading at HK
Beijing Biostar Pharms (2563) has a market capitalization of approximately HK$769M, trading at HK
Beijing Biostar Pharms's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Beijing Biostar Pharms runs a net profit margin of -394.4%, a gross margin of 92.1%, and an operating margin of -403.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Beijing Biostar Pharms reported revenue of HK
Beijing Biostar Pharms does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Beijing Biostar Pharms carries a debt-to-equity ratio of 0.00x and a current ratio of 8.33x, with a market beta of -0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Biostar Pharms (2563) the key facts are: market cap HK$769M, revenue HK
Get Beijing Biostar Pharms's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.